Patient Advocacy Funding
Pharmalot

Millions in fines are adding up as clinical trial information goes unreported

By Ed Silverman

Kopy Katz
Adam's Take

Marinus Pharma finds the biotech imitation game can only last so long

By Adam Feuerstein

Acne
Biotech

Dermira discontinues development of acne drug after two late-stage trials fail

By Adam Feuerstein

neurological cognitive tests - Alzheimers
First Opinion

FDA’s updated standards remove an unnecessary barrier to testing Alzheimer’s drugs

By Howard M. Fillit

Jonathan Kimmelman
In the Lab

How well can you predict the outcome of clinical trials? Not as well as you may think

By Andrew Joseph

Medical syringe
Health

Unregulated herpes experiments expose ‘black hole’ of accountability

By Marisa Taylor — Kaiser Health News

Treadmill
First Opinion

Why did it take the CDC so long to reverse course on debunked treatments for chronic fatigue syndrome?

By Julie Rehmeyer and David Tuller

Streptococcus pneumoniae bacteria
Biotech

Nabriva novel antibiotic meets goals in late-stage bacterial pneumonia study

By Adam Feuerstein

John Maraganore
Business

Stakes are high as Alnylam awaits results from novel rare disease therapy

By Adam Feuerstein

Neurons
Business

5 things to know about Sage’s must-win drug trials in postpartum depression

By Adam Feuerstein

Tapeworm Cancer ChestXRay
Pharma

AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients

By Adam Feuerstein

Neurons
Biotech

7 things to know about Sage Therapeutics’ pivotal trial of a drug for severe epilepsy

By Adam Feuerstein

Chemo Drip
Biotech

Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questions

By Adam Feuerstein

Cancer Care Costs
First Opinion

How do we solve the crisis in cancer communication?

By Lynn O'Connor Vos

Jesi Stracham
Health

Experimental scaffold hasn’t reversed her paralysis, but she’s embraced life ‘with wheels as legs’

By Rebecca Robbins

Cancer treatment
Gut Check

Do cancer clinical trials exaggerate the real-world benefits of drugs?

By Sharon Begley

Hepatitis Drugs
Pharmalot

How much longer will Gilead wait before buying its way out of the doldrums?

By Ed Silverman

Colontown
Health

‘Colontown’ gives cancer patients an edge in finding new treatments

By David Steen Martin

Right-to-Try Laws
First Opinion

Right-to-try laws could curtail the development of innovative new therapies

By Alison Bateman-House

Compassionate use panel illustration
Business

Novel system to get dying patients an experimental cancer drug raises hopes — and thorny questions

By Karen Weintraub

Sanofi
Pharmalot

What clinical trial results? Now you can see who isn’t sharing their findings

By Ed Silverman

Data Sharing
First Opinion

In defense of data sharing, but done in the right way

By Jeffrey M. Drazen and Isaac S. Kohane

Broken leg
In the Lab

Major trial casts doubt on leading device to heal bone fractures

By Charles Piller

Review board
First Opinion

Assess institutional review boards by their quality of decisions, not ownership

By Stephen Rosenfeld and Jim Gearhart

Pharmalot

Pharmalot, Pharmalittle: Drug makers are making huge bets on some cancer meds

By Ed Silverman

Zmapp
In the Lab

Amid crisis, Ebola drug narrowly missed threshold to prove effectiveness

By Andrew Joseph

Homeopathic pills
In the Lab

Should researchers study bunk science? Among respected scientists, a debate ensues

By Helen Branswell

Pharmalot

Pharmalot, Pharmalittle: Alnylam stock plunges after key clinical trial is ended

By Ed Silverman

Rachel Lefebvre
Health

For cancer patients, newest treatments force the ultimate decision, with no room for error

By Bob Tedeschi

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy